文献速递神经核医学肿瘤 PET/CT

18F-(2S,4R)-4-氟谷氨酰胺PET/CT在胶质瘤中的临床价值

Clinical Value of 18 F-(2S,4R)-4-Fluoroglutamine PET/CT in Glioma.
PubMed 文献 · Clin Nucl Med · 2024-12-24

研究纳入23例MRI疑诊胶质瘤患者,行18F-FGln PET/CT,评估SUVmax、SUVmean、MTV、TLG。23例中19例FGln-PET阳性。高、低级别胶质瘤SUVmax分别为4.75±2.21和1.00±0.66(P<0.001)。结论认为FGln PET/CT在鉴别胶质瘤分级方面尚不满意,但显示其在识别胶质瘤分期和IDH突变状态方面有潜力。

要点

  • 高、低级别胶质瘤的18F-FGln SUVmax分别为4.75±2.21和1.00±0.66(P<0.001)。
  • SUVmax、SUVmean、TLG与胶质瘤分级相关,r分别为0.667、0.693、0.487。
  • IDH野生型与突变型胶质瘤SUVmax分别为2.95±1.99和6.13±2.16(P=0.005)。

核心结论

  • 作者不认为18F-FGln PET/CT在胶质瘤鉴别诊断中令人满意,但揭示其在识别胶质瘤分期和IDH突变状态方面的潜力,并提出基于谷氨酰胺的PET显像能够评估胶质瘤的代谢营养摄取,以辅助临床诊断和治疗。

研究设计与样本

  • 纳入MRI疑诊胶质瘤的患者,行脑部静态和/或动态18F-FGln PET/CT,评估PET参数SUVmax、SUVmean、MTV和TLG,共23例纳入分析。

主要发现

  • 23例中19例18F-FGln PET阳性。
  • 高级别胶质瘤SUVmax为4.75±2.21,低级别胶质瘤为1.00±0.66(P<0.001)。
  • FGln-PET SUVmax、SUVmean、TLG均与胶质瘤分级呈统计学显著相关,相关系数r分别为0.667(P<0.001)、0.693(P<0.001)、0.487(P=0.021)。
  • ROC曲线分析显示SUVmax、SUVmean、TLG对胶质瘤分级具有较高区分性能,曲线下面积分别为0.976(95%CI 0.918-1)(P=0.002)、0.976(95%CI 0.918-1)(P=0.002)、0.835(95%CI 0.628-1.000)(P=0.026)。
  • IDH野生型胶质瘤SUVmax为2.95±1.99,IDH突变型为6.13±2.16(P=0.005);SUVmax和SUVmean对IDH状态具有良好至满意的区分性能,曲线下面积分别为0.885(95%CI 0.734-1.000)(P=0.009)和0.942(95%CI 0.828-1)(P=0.002)。

关键数值与推荐

  • 高级别胶质瘤SUVmax 4.75±2.21 vs 低级别胶质瘤1.00±0.66(P<0.001)。
  • SUVmax与胶质瘤分级相关r=0.667(P<0.001),SUVmean r=0.693(P<0.001),TLG r=0.487(P=0.021)。
  • SUVmax区分胶质瘤分级的AUC 0.976(95%CI 0.918-1)(P=0.002),SUVmean AUC 0.976(95%CI 0.918-1)(P=0.002),TLG AUC 0.835(95%CI 0.628-1.000)(P=0.026)。
  • IDH野生型胶质瘤SUVmax 2.95±1.99 vs IDH突变型6.13±2.16(P=0.005)。
  • SUVmax区分IDH状态的AUC 0.885(95%CI 0.734-1.000)(P=0.009),SUVmean AUC 0.942(95%CI 0.828-1)(P=0.002)。

临床怎么用

  • 作者提出基于谷氨酰胺的PET显像能够评估胶质瘤的代谢营养摄取,以辅助临床诊断和治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PROPOSE: The aim of this study was to evaluate the clinical application value of 18 F-FGln PET/CT in glioma. PATIENTS AND METHODS: Patients with suspected gliomas by MRI were included in this study. Static and/or dynamic brain 18 F-FGln PET/CT was performed. The PET parameters SUV max , SUV mean , MTV, and TLG were evaluated. RESULTS: Twenty-three patients were included in the analysis. Nineteen of 23 patients were positive for 18 F-FGln PET. The SUV max of high- and low-grade gliomas were 4.75 ± 2.21 and 1.00 ± 0.66 ( P < 0.001), respectively. FGln-PET SUV max , SUV mean , and TLG all showed statistically significant correlations with glioma grade, with correlation coefficients ( r ) of 0.667 ( P < 0.001), 0.693 ( P < 0.001), and 0.487 ( P = 0.021), respectively. Additionally, the SUV max , SUV mean , and TLG exhibited higher distinguishing performance for glioma grade by receiver operating characteristic curve analysis. The areas under the receiver operating characteristic curve of SUV max , SUV mean , and TLG were 0.976 (95% confidence interval [CI], 0.918-1) ( P = 0.002), 0.976 (95% CI, 0.918-1) ( P = 0.002), and 0.835 (95% CI, 0.628-1.000) ( P = 0.026), respectively. For glioma isocitrate dehydrogenase (IDH) mutation status, the SUV max of IDH wildtype and mutant glioma were 2.95 ± 1.99 and 6.13 ± 2.16 ( P = 0.005), respectively. The SUV mean and SUV max had good-to-satisfactory performance for IDH status with the area under the receiver operating characteristic curve of SUV max and SUV mean of 0.885 (95% CI, 0.734-1.000) ( P = 0.009) and 0.942 (95% CI, 0.828-1) ( P = 0.002). CONCLUSIONS: Although we do not assert that 18 F-FGln PET/CT imaging is satisfactory in the differential diagnosis of glioma, we revealed its potential for identifying the stage of gliomas and the IDH mutation status and propose that glutamine-based PET imaging enables the assessment of metabolic nutrient uptake of gliomas to assist clinical diagnosis and treatment of patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Xu X, Zhao H, Liu F, et al. Clinical Value of 18 F-(2S,4R)-4-Fluoroglutamine PET/CT in Glioma. Clin Nucl Med. 2024. PMID: 39668484. doi:10.1097/RLU.0000000000005581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。